Herpes Zoster – Epidemiology – Mature Markets Data
DRG Epidemiology’s coverage of herpes zoster (HZ) comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets. We report the incidence of HZ for each country, as well as annualized case counts projected to the national population.
Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.
DRG Epidemiology’s HZ forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living withHZ?
- Of all people with HZ, how many in each country have been formally diagnosed?
- Of all people diagnosed with HZ, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HZ over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following HZ patient populations:
- Total prevalent cases.
- Diagnosed prevalent cases.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Table of contents
- Herpes Zoster - Epidemiology - Mature Markets Data
- Introduction
- Key Findings
- Key Updates
- Incidence of Herpes Zoster per 1,000 per Year People of All Ages in 2021ttttt
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Events of Herpes Zoster Over the Next 20 Yearsttttttttt
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Incident Events
- Diagnosed Recurrent Events
- Total Diagnosed Events
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Herpes Zoster
- Studies Excluded from the Analysis of Herpes Zoster
- Risk/Protective Factors
- Risk/Protective Factors for Herpes Zoster
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.